Enhabit, Inc. (NYSE:EHAB) Short Interest Down 5.4% in January

Enhabit, Inc. (NYSE:EHAB) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 1,220,000 shares, a drop of 5.4% from the December 31st total of 1,290,000 shares. Based on an average trading volume of 375,300 shares, the short-interest ratio is presently 3.3 days. Currently, 2.8% of the shares of the stock are sold short.

Insider Transactions at Enhabit

In other news, Director Jeffrey Bolton purchased 4,000 shares of Enhabit stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the transaction, the director now directly owns 98,144 shares in the company, valued at approximately $852,871.36. This represents a 4.25 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stuart M. Mcguigan purchased 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average cost of $8.81 per share, with a total value of $132,150.00. Following the completion of the acquisition, the director now directly owns 46,810 shares in the company, valued at approximately $412,396.10. This represents a 47.15 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is owned by insiders.

Institutional Trading of Enhabit

Several large investors have recently modified their holdings of EHAB. Franklin Resources Inc. increased its stake in shares of Enhabit by 19.6% in the 3rd quarter. Franklin Resources Inc. now owns 32,382 shares of the company’s stock valued at $256,000 after purchasing an additional 5,317 shares during the last quarter. JPMorgan Chase & Co. grew its position in Enhabit by 37.8% in the third quarter. JPMorgan Chase & Co. now owns 305,245 shares of the company’s stock valued at $2,411,000 after acquiring an additional 83,707 shares during the last quarter. Marshall Wace LLP acquired a new position in Enhabit during the second quarter worth about $1,941,000. Systematic Financial Management LP lifted its holdings in shares of Enhabit by 12.2% in the third quarter. Systematic Financial Management LP now owns 1,838,199 shares of the company’s stock worth $14,522,000 after acquiring an additional 199,235 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Enhabit in the 3rd quarter valued at approximately $215,000.

Enhabit Stock Performance

EHAB traded up $0.06 on Monday, reaching $8.46. The company had a trading volume of 358,593 shares, compared to its average volume of 274,490. The stock has a market cap of $425.12 million, a P/E ratio of -3.64 and a beta of 1.83. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. Enhabit has a fifty-two week low of $6.85 and a fifty-two week high of $11.74. The company’s fifty day moving average is $7.98 and its 200 day moving average is $8.05.

Enhabit (NYSE:EHAB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). The firm had revenue of $253.60 million for the quarter, compared to the consensus estimate of $261.69 million. Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. During the same quarter in the previous year, the business earned $0.03 EPS. As a group, analysts predict that Enhabit will post 0.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EHAB has been the topic of a number of recent analyst reports. Leerink Partners restated a “market perform” rating and set a $8.00 target price (down previously from $8.50) on shares of Enhabit in a report on Tuesday, November 19th. Jefferies Financial Group upgraded shares of Enhabit from a “hold” rating to a “buy” rating and boosted their price objective for the company from $8.25 to $9.50 in a report on Monday, December 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.75.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.